Dr. Paul Strijbos is a neuroscientist with over 25 years of clinical development experience across the product lifecycle. He works as Neurotechnology Innovation Leader in the late-stage Neuroscience organization of F. Hoffmann-La Roche in Basel, Switzerland. Dr. Strijbos’s focus area is the development, validation, and regulatory qualification of digital clinical outcome assessments for the measurement of functional disease progression of patients living with neuromuscular diseases and movement impairments. He is a co-inventor of SV95C, the first regulatory-qualified digital outcome measure for use in pivotal studies. Prior to Roche, Dr. Strijbos worked at Novartis, Johnson & Johnson, and GlaxoSmithKline.